Bydureon reps better start looking

Quote

anonymous

Guest
I'm a Bydureon rep in the southwest and the injectable reps better start applying for jobs. AZ has no commitment to this product as seen by the new SIP program for Farxiga, budgets and territory alignments. We were short handed before with Tophers idiotic decisions, but I am now competing against a minimum of sixteen+ competitor reps by myself. I'm not saying that I'm not up for the challenge, but lets be realistic. The diabetes portfolio or Byrdureon won't be part of AZ a year from now.
 




Unfortunately, this is true. When Pascal did his review of key areas for growth it wasn't Diabetes. It was Farxiga alone. No Bydureon, etc. Onglyza was being worked out. This is all on the video. 3 Billion a year for Farxiga by 2020 and no mention of injectables, at all. I think we are all in Diabetes being set-up for a fire sale. Oncology is the meat and potatoes of where they want to go. What's sad is how hard we have worked for all of this but alas, this is the industry. If I was younger, I would find a new career for sure. Who wants to do this every year and prove you are better than your partner???
 








Top Bottom
Back
Quote